The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients
Open accessAbstract
Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been documented. We evaluated the efficacy of mitotane treatment of 96 patients with adrenocortical carcinoma followed up in our department between 1959 and 1992. Complete tumour resection was the goal of the initial treatment. Mitotane treatment was classified according to serum trough concentrations on maintenance therapy: low (< 14 mg l-1) or high (> or = 14 mg l-1). Total tumour resection was feasible in 47 patients (49%), and subtotal resection was performed in 37 patients (39%). Patients who underwent total tumour resection survived significantly longer than those who did not (P < 0.001). Adjuvant mitotane therapy (n = 11) did not influence survival after total resection. Sixty-two patients were given mitotane treatment at some time during their illness, only 30 of whom reached high maintenance serum levels. Mitotane treatment with high serum levels had an independently favourable influence on patient survival, using univariate (P < 0.01) and multivariate analysis (P = 0.01). Mitotane treatment resulting in low serum levels was tantamount to not giving mitotane at all. We conclude that mitotane treatment in adrenocortical carcinoma is effective only when high serum levels can be achieved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Hutter, A. M., & Kayhoe, D. E. (1966) · The American Journal of Medicine · doi:10.1016/0002-9343(66)90219-1 · Cited by 276
Hutter, A. M., & Kayhoe, D. E. (1966) · The American Journal of Medicine · doi:10.1016/0002-9343(66)90220-8 · Cited by 271
Macfarlane, D. A. (1958) · PubMed · Cited by 263
Bertagna, C., & Orth, D. N. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90384-3 · Cited by 245
Clinical and pathophysiologic aspects of adrenocortical carcinoma
Lipsett, M. B., Hertz, R., & Ross, G. T. (1963) · The American Journal of Medicine · doi:10.1016/0002-9343(63)90179-7 · Cited by 237
Mitotane Use in Inoperable Adrenal Cortical Carcinoma
Lubitz, J. A. (1973) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1973.03220100011003 · Cited by 224
van Slooten, H., Moolenaar, A. J., van Seter, A. P., & Smeenk, D. (1984) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(84)90033-6 · Cited by 198
Using and understanding medical statistics
Buyse, M. E. (1988) · Controlled Clinical Trials · doi:10.1016/0197-2456(88)90014-1 · Cited by 80
Mitotane increases the blood levels of hormone-binding proteins
van Seters, A. P., & Moolenaar, A. J. (1991) · European Journal of Endocrinology · doi:10.1530/acta.0.1240526 · Cited by 79
Moolenaar, A. J., van Slooten, H., van Seters, A. P., & Smeenk, D. (1981) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00258213 · Cited by 72
o,p'DDD Therapy in Invasive Adrenocortical Carcinoma
Becker, D. I., & SCHUMACHER, O. P. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-5-677 · Cited by 60
Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16)
Johnson, D. H., & Greco, F. (1986) · Cancer · Cited by 58
CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma.
van Slooten, H., & van Oosterom, A. T. (1983) · PubMed · Cited by 52
Samaan, N. A., & Hickey, R. C. (2007) · American Registry of PathologyWashington, DC eBooks · doi:10.55418/9781881041016-05 · Cited by 38
Metastatic adrenal cortical carcinoma. Prolonged regression with mitotane therapy
Jarabak, J. (1981) · JAMA · doi:10.1001/jama.246.15.1706 · Cited by 30
Estimation of o,p'-DDD in plasma by gas-liquid chromatography
Moolenaar, A. J., Niewint, J. W. M., & Oei, I. T. (1977) · Clinica Chimica Acta · doi:10.1016/0009-8981(77)90098-5 · Cited by 24
Connors, M. H. (1978) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1978.02120340112027 · Cited by 23
Mitotane Therapy of Adrenocortical Carcinoma
Haak, H. R., van Seters, A. P., & Moolenaar, A. J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199009133231115 · Cited by 8
Self-citationVenkatesh (1989) · doi:10.1002/1097-0142(19890801)64:3
Cited by
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Self-citationElse, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 873
Self-citationAdrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 764
Metadata
- Authors
- Haak, H., Hermans, J., van de Velde, C., Lentjes, E., Goslings, B., Fleuren, G.-J., & Krans, H.
- Venue
- British Journal of Cancer
- Published
- 1994-05
- Volume
- 69
- Issue
- 5
- Pages
- 947-951
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2079874148
- Cited by
- 329
- References
- 20
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.